Molecular Breast Imaging

Comparison of RCC mammogram and RCC BSGI

 

Breast-Specific Gamma Imaging (BSGI) is a Molecular Breast Imaging (MBI) technique that is advancing the early detection of breast cancer, especially in difficult-to-diagnose patients. As an adjunct to mammography, BSGI utilizes the Dilon 6800® Gamma Camera to help physicians see the breast more clearly and differentiate between benign from malignant tissue.

The Procedure

With BSGI/MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells. Therefore, malignant cells generally appear as “dark spots” on the BSGI image.

BSGI/MBI has very high sensitivity for identifying earlier stage cancers — as small as 1 mm as shown in clinical studies; and with a Negative Predictive Value (NPV) comparable to MRI.

The Dilon 6800® Gamma Camera is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI/MBI. This advanced imaging procedure can help physicians:
  • identify lesions independent of tissue density
  • duplicate standard mammographic views
  • discover early stage cancers

Dilon 6800, small field-of-view-gamma camera (anatomically specific)


BSGI/MBI aids in the effective management of suspicious and difficult-to-interpret breast cases.

More specifically, BSGI/MBI with the Dilon 6800®:
  • significantly aids in the differentiation of benign and malignant tissue
  • results in lower false positive rates with fewer patient restrictions than MRI
  • is sensitive to small non-palpable lesions
  • provides very high sensitivity for detecting DCIS and lobular carcinomas
  • helps evaluate the need and localize areas of interest for biopsy
  • aids in determining the extent of disease
  • can help monitor neoadjuvant tumor therapy
right_image
Print this page
Send this page to a friend
bottom